A review on qualifications and cost effectiveness of induced pluripotent stem cells (IPSCs)-induced cardiomyocytes in drug screening tests.
Arch Physiol Biochem
; 129(1): 131-142, 2023 Feb.
Article
in En
| MEDLINE
| ID: mdl-32783745
ABSTRACT
Human induced pluripotent stem cells (hIPSCs) have initiated a higher degree of successes in disease modelling, preclinical evaluation of drug therapy and pharmaco-toxicological testing. Since the discovery of iPSCs in 2006, many advanced techniques have been introduced to differentiate iPSCs to cardiomyocytes, which have been progressively improved. The disease models from iPSC-induced cardiomyocytes (iPSC-CM) have been successfully helping to study a variety of cardiac diseases such as long QT syndrome, drug-induced long QT, different cardiomyopathies related to mutations in mitochondria or desmosomal proteins and other rare genetic diseases. IPSC-CMs have also been used to screen the role of chemicals in cardiovascular drug discovery and individualisation of drug dosages. In this review, the quality of current procedures for characterisation and maturation of iPSC-CM lines will be discussed. Also, we will focus on time efficiency and cost of standard differentiation methods after reprogramming.
Key words
Full text:
1
Database:
MEDLINE
Main subject:
Induced Pluripotent Stem Cells
Type of study:
Diagnostic_studies
/
Health_economic_evaluation
/
Screening_studies
Limits:
Humans
Language:
En
Year:
2023
Type:
Article